karenitecin

DRUG4 trials

Sponsors

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), H. Lee Moffitt Cancer Center and Research Institute, BioNumerik Pharmaceuticals, Inc.

Conditions

Brain and Central Nervous System TumorsLung CancerMalignant MelanomaOvarian Cancer

Phase 1

Karenitecin in Treating Patients With Recurrent Malignant Glioma

CompletedNCT00014521

National Cancer Institute (NCI)Brain and Central Nervous System Tumors

Start: 2002-01-31Updated: 2008-07-24

Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

TerminatedNCT00358319

H. Lee Moffitt Cancer Center and Research InstituteMalignant Melanoma

Start: 2005-03-31End: 2007-04-30Updated: 2013-11-25

Phase 2

Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

CompletedNCT00010218

Alliance for Clinical Trials in OncologyLung Cancer

Start: 2001-04-30End: 2006-01-31Updated: 2016-07-19

Phase 3

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

CompletedNCT00477282

BioNumerik Pharmaceuticals, Inc.Ovarian Cancer

Start: 2007-08-31End: 2013-06-30Updated: 2020-03-12